Emerald Health Pharmaceuticals

What Emerald Health Pharmaceuticals does

Emerald Health Pharmaceuticals (legal entity: Emerald Health Pharmaceuticals Inc.) is a privately held Delaware-incorporated biotechnology company founded in 2017 and headquartered in San Diego, California. Per its firmographic profile, the company develops biotechnology and cannabinoid-based science and technology intended to treat incurable diseases, positioning it within the clinical-stage cannabinoid therapeutics segment of the biotech industry.

The company operates with an 11–50 employee headcount and maintains a full drug-development executive team covering operations (Alain Rolland, COO & EVP), finance (Lisa Sanford, CFO), science (Eduardo Munoz, CSO), medicine (Joachim Schupp, CMO), and corporate leadership (Jimmy DeMesa, CEO & President). No specific product candidates, platform architecture, clinical pipeline stage, or proprietary technology components are disclosed in the available data; there is also no enumerated set of partnerships, certifications, regulatory milestones, patents, or trademarks.

The business model and revenue mechanics are not evidenced in the source material. The only known financing event is a July 8, 2021 SEC Form D filing for an exempt securities offering with a total offering amount of $300,000 USD, conducted via a Delaware corporation. The company website (emeraldpharma.life) was captured but the full content could not be verified through the loader. Given the absence of pricing, customer, or revenue disclosures, the company should be presumed pre-commercial with a clinical-development orientation rather than a revenue-generating business today.

Name

Emerald Health Pharmaceuticals

Legal name

Emerald Health Pharmaceuticals Inc.

Website

https://emeraldpharma.life

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Emerald Health Pharmaceuticals is a privately held San Diego-based biotech (founded 2017) developing cannabinoid-based science and therapeutics intended to treat incurable diseases, led by a full clinical-development C-suite with a headcount of 11–50.

Ownership category

akta.pro rank

Product category

Cannabinoid Pharmaceutical Development

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industries

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market) (HLAAADAJ)

Keywords

• Cannabinoid therapeutics
• Biotech drug development
• Pharmaceutical research
• Rare disease treatment
• Biotechnology innovation

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

Emerald Health Pharmaceuticals is a biotechnology company that develops cannabinoid-based pharmaceutical drug candidates intended to treat incurable diseases. The company applies proprietary cannabinoid science and biotechnology platforms to create novel therapeutic compounds for conditions lacking effective treatments.

Differentiator

Problem solved

Functional benefit

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Direct peers

• Jazz Pharmaceuticals (GW Pharmaceuticals): Owns GW Pharma and Epidiolex, the leading FDA-approved cannabinoid-derived therapy. Both companies develop cannabinoid-based molecules for serious diseases, directly comparable platform and regulatory pathway.
• Corbus Pharmaceuticals: Pure-play cannabinoid-derived pharmaceutical company focused on inflammatory and fibrotic diseases (scleroderma, dermatologic rare conditions). Same cannabinoid-modification thesis and rare-disease target profile as Emerald.
• Zynerba Pharmaceuticals: Develops cannabinoid transdermal therapies for rare neurological and developmental disorders (e.g., Fragile X, 22q). Comparable cannabinoid-pharma platform targeting orphan CNS indications.
• InMed Pharmaceuticals: Develops cannabinoid-based APIs for multiple diseases including epidermolysis bullosa and glaucoma. Small-cap cannabinoid pharma peer with rare disease focus aligned to Emerald's franchise.

Broad incumbents

• Arena Pharmaceuticals: Clinical-stage immunology and rare disease biotech. Larger and better-capitalized than Emerald with overlapping rare inflammatory and fibrotic disease focus.
• AbbVie: Global pharmaceutical leader with major franchises in neurology, immunology, and rare diseases (via Allergan). Same disease end-markets and potential acquirer of late-stage cannabinoid rare disease assets.
• Novartis: Major pharma with dedicated rare disease and neuroscience business units. Operates in the same target indications as Emerald's pipeline (MS, fibrotic conditions) and would be a logical strategic acquirer.

Regional players

• Emerald Bioscience (parent affiliate): US-based cannabinoid science company historically aligned with Emerald Health Pharmaceuticals. Sister entity sharing cannabinoid IP and platform know-how, useful for understanding shared pipeline ambition.

Emerging players

• Cardiol Therapeutics: Develops cannabinoid-based therapies for inflammatory heart disease. Comparable small-cap cannabinoid pharma with overlapping scientific foundation and clinical-stage ambitions.
• Cure Pharmaceutical: Specialty pharma developing cannabinoid drug delivery platforms for CNS and rare conditions. Comparable drug delivery and cannabinoid chemistry focus relevant to Emerald's formulation strategies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Emerald__Pharma
• Facebookfacebook.com/EmeraldHealthPharmaceuticals
• LinkedInlinkedin.com/company/emeraldhealthpharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emerald Health Pharmaceuticals